Strong growth in Indian generics

Streamlining of laboratory portfolios, stricter regulations and an increase in the number of drugs approved by the FDA (Food and Drug Administration) have allowed Indian generics companies to boost their US market share by 5% in the last few months. They have now 40% of the overall American health market, worth close to $60 billion. In the first nine months of 2018, almost 100 generic drugs were authorized by the FDA, the American regulatory authority